{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:09:48Z","timestamp":1792789788078,"version":"4.5.0"},"reference-count":45,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FUNDACIO INSTITUT DE RECERCA HOSP STA CREU I SANT PAU"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: IgG4-related disease is a chronic fibro-inflammatory condition. Despite the development of classification and responder indexes, reliable biomarkers for disease activity and therapeutic monitoring remain limited. We evaluate the performance of a panel of biomarkers, including cytokine profiles, plasmablasts and conventional markers. Materials and Methods: We conducted a cross-sectional, single-center study, involving 35 patients diagnosed with IgG4-RD. Disease activity was evaluated using the IgG4-RD Responder Index (RI), Damage Index (DI) and clinical assessment. Laboratory evaluation included serum IgG4, total IgG, CRP, ESR, eosinophils, IgE, complement levels, and cytokine profiling via multiplex immunoassay. B cell subpopulations were analyzed by flow cytometry. Statistical analyses were performed using STATA\/BE 17.0. Results: Patients with active disease (RI &gt; 4 or clinical judgment) exhibited significantly higher levels of total IgG (p = 0.02), IgG4 (p = 0.01), and IL-5 (p = 0.03). PET-positive patients showed a Th1-skewed immune profile, with elevated IFN-\u03b3\/IL-4 (p &lt; 0.001), reduced IL-21\/IFN-\u03b3 (p = 0.03), and increased eosinophils (p = 0.03). Clinician-assessed active disease was associated with higher total IgG levels (p = 0.01). Treatment-specific effects were observed: prednisone was associated with lower IgG4 and C3 levels. Notably, plasmablasts did not consistently correlate with clinical or imaging activity scores, possibly reflecting treatment status or B cell dynamics. Conclusions: This study demonstrates that cytokine ratios, particularly those involving IL-5, IL-13, IL-21, and IFN-\u03b3, offer complementary information to traditional serological markers for IgG4-RD activity. While PET\/CT-defined activity was best reflected by biomarkers of an IFN-\u03b3-mediated pathway, the IgG4-RD RI demonstrated a stronger association with conventional humoral markers like serum IgG4 and total IgG. None of these biomarkers correlated with organ damage.<\/jats:p>","DOI":"10.3390\/medicina62020323","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T14:55:11Z","timestamp":1770216911000},"page":"323","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunological Biomarkers to Assess Activity and Treatment Response in IgG4-Related Disease"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8339-5420","authenticated-orcid":false,"given":"Patricia","family":"Moya-Alvarado","sequence":"first","affiliation":[{"name":"Rheumatology Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Multiorgan Damage and Rheumatology Research Group, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lopez-Gomez","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Rheumatology Department, Complex Hospitalari Universitari Mois\u00e8s Broggi, 08970 Sant Joan Desp\u00ed, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-158X","authenticated-orcid":false,"given":"Laura","family":"Mart\u00ednez-Martinez","sequence":"additional","affiliation":[{"name":"Immunology Department, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Universitat Aut\u00f2noma de Barcelona, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4972-9527","authenticated-orcid":false,"given":"Hye Sang","family":"Park","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Multiorgan Damage and Rheumatology Research Group, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Franco","family":"Leyva","sequence":"additional","affiliation":[{"name":"Immunology Department, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Universitat Aut\u00f2noma de Barcelona, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar Concepci\u00f3n","family":"Mart\u00edn","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9883-9845","authenticated-orcid":false,"given":"Helena","family":"Codes-Mendez","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Multiorgan Damage and Rheumatology Research Group, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9960-991X","authenticated-orcid":false,"given":"Anna Calvet","family":"Lacruz","sequence":"additional","affiliation":[{"name":"Immunology Department, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Universitat Aut\u00f2noma de Barcelona, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Calleja","sequence":"additional","affiliation":[{"name":"Immunology Department, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Universitat Aut\u00f2noma de Barcelona, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Magallares","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Multiorgan Damage and Rheumatology Research Group, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5410-5807","authenticated-orcid":false,"given":"Iv\u00e1n","family":"Castellv\u00ed","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Multiorgan Damage and Rheumatology Research Group, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio J.","family":"Barros-Membrilla","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0428-3399","authenticated-orcid":false,"given":"Julia","family":"Bern\u00e1rdez","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Multiorgan Damage and Rheumatology Research Group, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7738-6787","authenticated-orcid":false,"given":"H\u00e8ctor","family":"Corominas","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Multiorgan Damage and Rheumatology Research Group, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/s10165-011-0508-6","article-title":"A novel clinical entity, IgG4-related disease (IgG4RD): General concept and details","volume":"22","author":"Umehara","year":"2012","journal-title":"Mod. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"rkae020","DOI":"10.1093\/rap\/rkae020","article-title":"Current and future advances in practice: IgG4-related disease","volume":"8","author":"Wallace","year":"2024","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e950212","DOI":"10.12659\/MSM.950212","article-title":"IgG4-Related Disease: A Review of Persistent Challenges in the Pathogenesis, Diagnosis, and Approaches to Treatment","volume":"31","author":"Parums","year":"2025","journal-title":"Med. Sci. Monit."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2018-214603","article-title":"Clinical phenotypes of IgG4-related disease: An analysis of two international cross-sectional cohorts","volume":"78","author":"Wallace","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1093\/rheumatology\/keaa221","article-title":"Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes","volume":"59","author":"Lanzillotta","year":"2020","journal-title":"Rheumatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"m1067","DOI":"10.1136\/bmj.m1067","article-title":"Advances in the diagnosis and management of IgG4 related disease","volume":"369","author":"Lanzillotta","year":"2020","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5125\/jkaoms.2020.46.1.3","article-title":"Review of a novel disease entity, immunoglobulin G4-related disease","volume":"46","author":"Maehara","year":"2020","journal-title":"J. Korean Assoc. Oral. Maxillofac. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14397595.2019.1650694","article-title":"Pathogenesis of IgG4-related disease. Comparison with Sj\u00f6gren\u2019s syndrome","volume":"30","author":"Tsuboi","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1136\/annrheumdis-2014-205799","article-title":"B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease","volume":"74","author":"Feeney","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdsr.2022.12.002","article-title":"Immune dysregulation in immunoglobulin G4-related disease","volume":"59","author":"Maehara","year":"2023","journal-title":"Jpn. Dent. Sci. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.imlet.2019.01.008","article-title":"IL-10(+) T follicular regulatory cells are associated with the pathogenesis of IgG4-related disease","volume":"207","author":"Ito","year":"2019","journal-title":"Immunol. Lett."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.semarthrit.2019.06.018","article-title":"Biomarkers in IgG4-related disease: A systematic review","volume":"50","author":"Tang","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/annrheumdis-2014-205233","article-title":"Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations","volume":"74","author":"Wallace","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.cgh.2017.02.007","article-title":"Increases in IgE, Eosinophils, and Mast Cells Can be Used in Diagnosis and to Predict Relapse of IgG4-Related Disease","volume":"15","author":"Culver","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lopez-Gomez, M., Moya-Alvarado, P., Park, H.S., Mart\u00edn, M.C., Calleja, S., Codes-Mendez, H., Magallares, B., Castellv\u00ed, I., Barros-Membrilla, A.J., and Laiz, A. (2024). Comparative Analysis of Classification Criteria in IgG4-Related Disease and Evaluating Diagnostic Accuracy from a Retrospective Cohort in Clinical Practice. Diagnostics, 14.","DOI":"10.3390\/diagnostics14222583"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/art.41120","article-title":"The 2019 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for IgG4-Related Disease","volume":"72","author":"Wallace","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/art.39132","article-title":"International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease","volume":"67","author":"Khosroshahi","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.27435","article-title":"Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease","volume":"62","author":"Khosroshahi","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: A prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"259408","DOI":"10.1155\/2012\/259408","article-title":"Development of an IgG4-RD Responder Index","volume":"2012","author":"Carruthers","year":"2012","journal-title":"Int. J. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/acr.23543","article-title":"An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index","volume":"70","author":"Wallace","year":"2018","journal-title":"Arthritis Care Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e003938","DOI":"10.1136\/rmdopen-2023-003938","article-title":"The development and initial validation of IgG4-related disease damage index: A consensus report from Chinese IgG4-RD Consortium","volume":"10","author":"Peng","year":"2024","journal-title":"RMD Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"20210105","DOI":"10.1259\/bjr.20210105","article-title":"(18)F-FDG PET\/CT Manifestations of IgG4-related Disease","volume":"94","author":"Tang","year":"2021","journal-title":"Br. J. Radiol."},{"key":"ref_24","unstructured":"StataCorp (2021). Stata Statistical Software, Release 17, StataCorp LLC."},{"key":"ref_25","unstructured":"R Core Team (2021). A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: https:\/\/www.r-project.org\/."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","article-title":"IgG4-related disease","volume":"385","author":"Kamisawa","year":"2015","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/art.39205","article-title":"IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients","volume":"67","author":"Wallace","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_28","first-page":"1038","article-title":"Role of eosinophilia in IgG4-related disease","volume":"40","author":"Ming","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/joim.12942","article-title":"Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: A long-term cohort study","volume":"286","author":"Peng","year":"2019","journal-title":"J. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"16483","DOI":"10.1038\/s41598-019-52847-6","article-title":"Different clinical patterns of IgG4-RD patients with and without eosinophilia","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10238-025-01741-9","article-title":"Elevated eosinophil-to-lymphocyte ratio (ELR) as a predictor of relapse for IgG4-related disease: A retrospective study across a decade","volume":"25","author":"Zhang","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100047","DOI":"10.1016\/j.jtauto.2020.100047","article-title":"Immunological mechanism of IgG4-related disease","volume":"3","author":"Liu","year":"2020","journal-title":"J. Transl. Autoimmun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nri.2017.90","article-title":"Type 2 immunity in tissue repair and fibrosis","volume":"18","author":"Gieseck","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jaci.2019.07.004","article-title":"B lymphocytes directly contribute to tissue fibrosis in patients with IgG(4)-related disease","volume":"145","author":"Rigamonti","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.alit.2024.07.005","article-title":"Human T follicular helper cells and their impact on IgE and IgG4 production across allergy, malignancy, and IgG4-related disease","volume":"74","author":"Akiyama","year":"2025","journal-title":"Allergol. Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.39209","article-title":"Number of circulating follicular helper 2 T cells correlates with IgG4 and interleukin-4 levels and plasmablast numbers in IgG4-related disease","volume":"67","author":"Akiyama","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kwon, O.C., Park, M.C., and Kim, Y.G. (2022). Correlation between serologic parameters and disease activity of IgG4-related disease: Differences between patients with normal and elevated serum IgG4 concentrations. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1020459"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3324\/haematol.2018.205526","article-title":"IgG4-related disease: What a hematologist needs to know","volume":"104","author":"Chen","year":"2019","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/hep.21697","article-title":"Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis","volume":"45","author":"Zen","year":"2007","journal-title":"Hepatology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/art.33320","article-title":"Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease","volume":"64","author":"Tanaka","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1080\/14397595.2018.1526357","article-title":"Interleukin 5-producing ST2(+) memory Th2 cells in IgG4-related dacryoadenitis and sialadenitis","volume":"29","author":"Yamamoto","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1080\/14397595.2018.1436029","article-title":"Stage classification of IgG4-related dacryoadenitis and sialadenitis by the serum cytokine environment","volume":"28","author":"Yamamoto","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jaci.2014.03.034","article-title":"De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease","volume":"134","author":"Mattoo","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/mr\/roac097","article-title":"Glucocorticoids in the treatment of IgG4-related disease-Prospects for new international treatment guidelines","volume":"33","author":"Yoshifuji","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-021-02481-3","article-title":"Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: A prospective cohort study","volume":"23","author":"Peng","year":"2021","journal-title":"Arthritis Res. Ther."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/2\/323\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:09:31Z","timestamp":1770289771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/2\/323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["medicina62020323"],"URL":"https:\/\/doi.org\/10.3390\/medicina62020323","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]}}}